The effect of a combination therapy with myo-inositol and a combined oral contraceptive pillversusa combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome
- 21 March 2011
- journal article
- research article
- Published by Taylor & Francis Ltd in Gynecological Endocrinology
- Vol. 27 (11), 920-924
- https://doi.org/10.3109/09513590.2011.564685
Abstract
Aim. Compare the effects of a combined contraceptive pill (OCP) in combination with myo-inositol (MI) on endocrine, metabolic, and clinical parameters in patients with polycystic ovary syndrome (PCOS). Methods. One hundred fifty-five patients with PCOS were enrolled in this prospective, open-label clinical study. Patients were assigned to receive oral treatment with OCP alone (estradiol (EE) 30 μg/gestodene 75 μg) or in combination with myo-inositol 4 g/die, for 12 months. Results. OCP plus MI therapy resulted in a higher reduction of FG score compared with OCP alone therapy. The combined therapy (OCP plus MI) significantly decreased hyperinsulinaemia, by positively affecting the fasting insulin and glucose levels and homeostasis model assessment-insulin resistance parameters, while no significant changes were observed in the OCP group. Androgens serum levels decreased in both groups, but significantly more in the combined therapy group. The lipid profile was improved in the combined therapy group, by reducing low-density lipoprotein cholesterol levels and enhancing high-density lipoprotein cholesterol levels. Conclusions. Our data show that a combination of combined contraceptive pill and MI may be more effective in controlling endocrine, metabolic, and clinical profile in patients with PCOS than OCP alone, and may reduce insulin levels and insulin resistance. Hence, combined treatment may become a more effective long-term therapeutic choice for controlling PCOS symptoms.Keywords
This publication has 31 references indexed in Scilit:
- Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society GuidelineJournal of Clinical Endocrinology & Metabolism, 2006
- Prevalence and Characteristics of the Polycystic Ovary Syndrome in Overweight and Obese WomenArchives of Internal Medicine, 2006
- Encuesta sobre práctica clínica en el hiperparatiroidismo primarioEndocrinología y Nutrición, 2006
- The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary SyndromeEndocrine Reviews, 2005
- Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary SyndromeJournal of Clinical Endocrinology & Metabolism, 2005
- Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndromeBest Practice & Research Clinical Obstetrics & Gynaecology, 2004
- Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitusFertility and Sterility, 2002
- The Biochemical Basis for Increased Testosterone Production in Theca Cells Propagated from Patients with Polycystic Ovary SyndromeJournal of Clinical Endocrinology & Metabolism, 2001
- Smaller LDL particle size in women with polycystic ovary syndrome compared to controlsClinical Endocrinology, 2001
- Insulin and the Polycystic Ovary SyndromeThe New England Journal of Medicine, 1996